Tonix Pharmaceuticals Holding (TNXP) Interest & Investment Income (2015 - 2026)

Tonix Pharmaceuticals Holding has reported Interest & Investment Income for 12 years, with the latest figure at $1.4 million in Q2 2026.

• On a quarterly basis, Interest & Investment Income rose 51.86% year-over-year to $1.4 million in Q2 2026; TTM through Jun 2026 was $5.4 million, a 294.76% increase from a year earlier, with the FY2025 full-year figure at $4.1 million, up 18745.45% from the prior year.
• Interest & Investment Income was $1.4 million for Q2 2026 at Tonix Pharmaceuticals Holding, up from $1.3 million in the prior quarter.
• The five-year high for Interest & Investment Income was $1.4 million in Q2 2026, with the low at $1000.0 in Q2 2024.
• Average Interest & Investment Income over 5 years is $643625.0, with a median of $628000.0 recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Interest & Investment Income tumbled 99.85% in 2024, then surged 134300.0% in 2025.
• Over 5 years, Interest & Investment Income stood at $1.0 million in 2022, then tumbled by 38.36% to $646000.0 in 2023, then sank by 99.85% to $1000.0 in 2024, then soared by 134300.0% to $1.3 million in 2025, then gained by 6.55% to $1.4 million in 2026.
• The last three Interest & Investment Income figures came in at $1.4 million (Q2 2026), $1.3 million (Q1 2026), and $1.3 million (Q4 2025), per Business Quant data.